Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine

Sponsor

DreamTec Research Limited (Industry)

Overall Status

Completed

CT.gov ID

NCT05158855

Collaborator

DreamTec Cytokine Limited (Other)

Enrollment

Location

Arm

10.9

Actual Duration (Months)

1.5

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis spore extract which contain Spike protein of the SARS-COV2 on the spore coat.

Condition or Disease	Intervention/Treatment	Phase
COVID-19 Pandemic	Dietary Supplement: Bacillus subtilis spore extract	N/A

Detailed Description

COVID-19 immunization reduces the risk of COVID-19 and potentially serious complications. In clinical trials, all COVID-19 vaccines currently authorized for use in the United States are beneficial in protecting adults and children 5 years and older against COVID-19, including severe illness. So far, studies looking at how COVID-19 vaccines work in real-world conditions (vaccine effectiveness studies) have shown that they work well. However, it has been reported that most of the antibodies in people who received the second dose of COVID-19 vaccine had been dramatically decreased.

Bacillus subtilis (B. subtilis) is a generally regarded as safe organism and it is a common food source. The investigators have used an engineered Bacillus subtilis spore which express and display the spike protein receptor binding domain (sRBD) of the SARS-CoV-2 on the surface. The investigators have proved that it successfully increased the neutralizing antibody against sRBD in unvaccinated mice and human individuals after oral administration.

On this basis, the investigators designed and developed an oral antibody booster by extracting the spore surface of B. subtilis. This supplement has the advantage of being stable and effective, free of recombinant plasmid, and can be served as a potential antibody booster to existing vaccines.

Mice toxicity and efficacy test was conducted and the experiment proved that the B. subtilis spores extract was effective in inducing immune response, and it was safe and did not cause any significant adverse effect.

The B. subtilis spore extract will be further studied in a human trials through oral administration to test its safety and the immune effect resulted in human body.

Study Design

Study Type:

Interventional

Actual Enrollment :

16 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

Volunteers who vaccinated with COVID-19 vaccines for over 6 months will be recruited and will receive 1 capsule of neutralizing antibody booster. Their weight, blood pressure, and the concentration of neutralizing IgG antibody against receptor binding domain of spike protein in SARS-CoV2 will be measured before the oral administration and 14, 28 days after the administration. Number of adverse event from the beginning of the administration to 30 days after the administration will also be recorded.Volunteers who vaccinated with COVID-19 vaccines for over 6 months will be recruited and will receive 1 capsule of neutralizing antibody booster. Their weight, blood pressure, and the concentration of neutralizing IgG antibody against receptor binding domain of spike protein in SARS-CoV2 will be measured before the oral administration and 14, 28 days after the administration. Number of adverse event from the beginning of the administration to 30 days after the administration will also be recorded.

Masking:

None (Open Label)

Primary Purpose:

Prevention

Official Title:

Human Pilot Test of an Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine

Actual Study Start Date :

Jun 1, 2021

Actual Primary Completion Date :

Apr 20, 2022

Actual Study Completion Date :

Apr 30, 2022

Arms and Interventions

Arm	Intervention/Treatment
Experimental: neutralizing antibody booster for vaccinated participants participants after 6-month vaccinated with COVID-19 vaccine received 1 capsule of B. subtilis spore extract	Dietary Supplement: Bacillus subtilis spore extract Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronavirus. This product could have a vaccine like activity within the intestinal environment.

Arm

Intervention/Treatment

Experimental: neutralizing antibody booster for vaccinated participants

participants after 6-month vaccinated with COVID-19 vaccine received 1 capsule of B. subtilis spore extract

Dietary Supplement: Bacillus subtilis spore extract

Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronavirus. This product could have a vaccine like activity within the intestinal environment.

Outcome Measures

Primary Outcome Measures

To assess the safety of the engineered Bacillus subtilis spore coat extract [3 months]
To measure the weight changes in kilograms and number of incidence of adverse event from the beginning of the administration to 30 days after the administration
Concentration of Neutralizing IgG antibody against Receptor binding domain of spike protein of SARS-CoV2 [3 months]
To measure the concentration of Neutralizing IgG antibody against Receptor binding domain of spike protein of SARS-CoV2 before the administration and 14, 28 days after the administration

Eligibility Criteria

Criteria

Ages Eligible for Study:

12 Years to 85 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

healthy
age over 12 years
the outcome of the following examinations should be clinically insignificant: medical and surgical history (hypo-, hypertension, allergy, other diseases, major surgery, micturition, defecation, sleep, illness within the last 4 weeks prior to the start of the trial);
participant vaccinated with COVID-19 over 6 months
anti-SARS CoV 2 neutralizing antibody is negative in serum.

Exclusion Criteria:

pregnant women
history of COVID-19 infection or showing COVID-19 infection symptoms
having had contact to people with known COVID-19 infection in the last 14 days
having fever (> 37.4oC in the last 24 hours), dry cough or feeling tired and having aches and pains, nasal congestion, runny nose, sore throat and diarrhea.
positive real time RT-PCR COVID-19 test.
persons with autoimmune diseases
allergic diathesis or any clinically significant allergic disease (i.e. asthma)
any condition that might impair the immune response
recent or current immunosuppressive medication
any other vaccine application 5 months before the first dose

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Macao Greater Bay Area Association of Healthcare Providers	Macau		Macau

Sponsors and Collaborators

DreamTec Research Limited
DreamTec Cytokine Limited

Investigators

Study Director: WAI YEUNG KWONG, PhD, DreamTec Cytokine Limited

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

DreamTec Research Limited

ClinicalTrials.gov Identifier:

NCT05158855

Other Study ID Numbers:

PRP/008/21FXBooster

First Posted:

Dec 15, 2021

Last Update Posted:

Jun 30, 2022

Last Verified:

Jun 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Plan to Share IPD:

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

COVID-19

Study Results

No Results Posted as of Jun 30, 2022